Alzheimer’s disease (AD), a type of dementia that affects memory, thinking, and behavior, accounts for 60-80% of dementia cases and is not considered a normal aspect of aging. Unfortunately, current diagnostic techniques are inaccurate, time-consuming, and drain financial resources. As new treatments for AD emerge, the need for a simple, definitive way to distinguish AD from other neurodegenerative conditions has gained urgency in the past few years.
The most promising breakthrough for identifying AD is an autopsy-confirmed, minimally invasive skin test to support clinicians’ definitive diagnosis of AD vs. other forms of dementia. This test has the potential to help patients and families get on the right treatment path for improved quality of life.
Impact of AD
